glp 1 drugs for insulin resistance GLP-1-based medications: Mechanisms involved in obesity treatment GLP-1 Agonists: A Comprehensive Overview

Development timeline : Survodutide Phase 3 results are expected sooner (H1 2026 for obesity), potentially reaching market before retatrutide

Unlike semaglutide, which targets only the GLP-1 receptor, tirzepatide is a dual-action medication that activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors

doi: Walker, E

It's important to acknowledge that these are common, with studies indicating that a significant percentage of users (reports range from 40% up to 85%) experience issues like nausea, vomiting, diarrhea, constipation, bloating, or heartburn, particularly when first starting the medication or increasing the dose

Aim for 20-30 minutes per meal to allow enough time to feel full